. . . . . . . . . . . . "[For EGFR TKI treated cancer recurrence patients, those with positive mutation-specific antibody IHC staining had better EGFR TKI response (pā€Š=ā€Š0.008) and longer progression-free survival (pā€Š=ā€Š0.012) than those without.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2014-02-25"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2014-10-02T12:40:20+02:00"^^ . . . . . . . . . . . "v2.1.0.0" . "v2.1.0" .